Goldman Sachs
RPTX

Goldman Sachs’s Repare Therapeutics RPTX Stock Holding History

Goldman Sachs’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-17,529
Closed -$24.4K – 6613
2025
Q2 		$24.4K Buy
+17,529
New +$22.9K ﹤0.01% 5968
2025
Q1 		– Sell
-110,906
Closed -$145K – 6360
2024
Q4 		$145K Buy
+110,906
New +$330K ﹤0.01% 5698
2024
Q3 		– Sell
-20,169
Closed -$66.6K – 6031
2024
Q2 		$66.6K Sell
20,169
-16,118
-44% -$57.5K ﹤0.01% 5443
2024
Q1 		$171K Buy
36,287
+7,349
+25% +$47.1K ﹤0.01% 5148
2023
Q4 		$211K Sell
28,938
-35,409
-55% -$198K ﹤0.01% 5131
2023
Q3 		$777K Sell
64,347
-671
-1% -$6.93K ﹤0.01% 4418
2023
Q2 		$688K Sell
65,018
-11,993
-16% -$124K ﹤0.01% 4566
2023
Q1 		$758K Buy
77,011
+12,567
+20% +$144K ﹤0.01% 4586
2022
Q4 		$948K Buy
64,444
+15,134
+31% +$226K ﹤0.01% 4456
2022
Q3 		$598K Sell
49,310
-765
-2% -$9.85K ﹤0.01% 4853
2022
Q2 		$700K Buy
50,075
+8,330
+20% +$98.1K ﹤0.01% 4857
2022
Q1 		$594K Buy
41,745
+10,649
+34% +$158K ﹤0.01% 5203
2021
Q4 		$656K Sell
31,096
-9,061
-23% -$213K ﹤0.01% 5185
2021
Q3 		$1.05M Sell
40,157
-26,461
-40% -$855K ﹤0.01% 4699
2021
Q2 		$2.08M Buy
66,618
+12,248
+23% +$401K ﹤0.01% 4169
2021
Q1 		$1.67M Buy
54,370
+36,487
+204% +$1.24M ﹤0.01% 4159
2020
Q4 		$613K Buy
+17,883
New +$534K ﹤0.01% 4492
2020
Q3 		– Sell
-12,353
Closed -$383K – 5514
2020
Q2 		$383K Buy
+12,353
New +$397K ﹤0.01% 4513

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return

Goldman Sachs's RPTX Position: Q3 2025 in Review

Goldman Sachs sold out of Repare Therapeutics (RPTX) in Q3 2025, closing a stake of 17,529 shares — an estimated $24.4K sold.

Goldman Sachs first reported a position in RPTX in Q2 2020 and held it in 18 quarters. The position peaked at $2.08M in Q2 2021. 45 funds tracked by Wall St. Rank hold RPTX as of Q3 2025.

  • Goldman Sachs reported no remaining Repare Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Goldman Sachs sold 17,529 Repare Therapeutics shares in Q3 2025, an estimated $24.4K.
  • Goldman Sachs first reported a position in Repare Therapeutics in Q2 2020 and held it in 18 quarters.
  • Goldman Sachs's Repare Therapeutics position peaked at $2.08M in Q2 2021.
  • 45 funds tracked by Wall St. Rank held Repare Therapeutics as of Q3 2025.

Based on Goldman Sachs's 13F filing for Q3 2025, filed 14 Nov 2025.